Genistein

Generic Name: Genistein

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₀O_₅

CAS Number: 446-72-0

Unique Ingredient Identifier: DH2M523P0H

Background: An isoflavonoid derived from soy products. It inhibits protein-tyrosine kinase and topoisomerase-II (DNA topoisomerases, type II) activity and is used as an antineoplastic and antitumor agent. Experimentally, it has been shown to induce G2 phase arrest in human and murine cell lines.
...

Indication: Currently Genistein is being studied in clinical trials as a treatment for prostate cancer.

Associated Conditions: Calcium Deficiency, Deficiency, Vitamin D, Osteodystrophy, Osteomalacia, Osteoporosis

Associated Therapies: -

Clinical Trials

Isoflavones and the Coronary Circulation in Men and Women With Coronary Artery Disease

Phase 2

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Placebo
Drug: Genistein

First Posted Date: 2006-02-07

Last Posted Date: 2019-08-05

Lead Sponsor: Imperial College London

Target Recruit Count: 71

Registration Number: NCT00287690

Locations: 🇬🇧
Royal Brompton & Harefield NHS Trust, London, United Kingdom

Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer

Phase 2

Completed

Conditions: Stage II Bladder Cancer AJCC v6 and v7
Recurrent Bladder Carcinoma
Stage III Bladder Cancer AJCC v6 and v7
Stage I Bladder Cancer AJCC v6 and v7

Interventions: Other: Laboratory Biomarker Analysis
Drug: Genistein
Other: Placebo Administration
Other: Pharmacological Study
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2005-07-11

Last Posted Date: 2021-06-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00118040

Locations: 🇺🇸
University of Wisconsin Chemoprevention Consortium, Madison, Wisconsin, United States
🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
🇺🇸
Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, United States

and more 7 locations

A Pharmacokinetic Study of Genistein, a Tyrosine Kinase Inhibitor

Phase 1

Completed

Conditions: Cancer

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT00001696

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

CVD Risk and Health in Postmenopausal Phytoestrogen Users

Phase 2

Completed

Conditions: Bone Diseases
Cardiovascular Diseases
Coronary Disease
Myocardial Ischemia
Postmenopause
Depression
Heart Diseases
Osteoporosis

First Posted Date: 1999-10-28

Last Posted Date: 2016-02-29

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Registration Number: NCT00000613

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy